Bevacizumab: overview of the literature

References

• Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J. Clin. Oncol.23(14), 3243–3256 (2005).
   PubMed Web of Science ®Google Scholar
• Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am. J. Health Syst. Pharm.62(10), 1021–1032 (2005).
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med.333(26), 1757–1763 (1995).
   PubMed Web of Science ®Google Scholar
• Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res.58(17), 4008–4014 (1998).
   PubMed Web of Science ®Google Scholar
• Nasu R, Kimura H, Akagi K, Murata T, Tanaka Y. Blood flow influences vascular growth during tumour angiogenesis. Br. J. Cancer79(5–6), 780–786 (1999).
   Google Scholar
• Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control9(Suppl. 2), 36–44 (2002).
   PubMedGoogle Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science235(4787), 442–447 (1987).
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell146(6), 873–887 (2011).
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science219(4587), 983–985 (1983).
   PubMed Web of Science ®Google Scholar
• Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann. Surg.175(3), 409–416 (1972).
   PubMed Web of Science ®Google Scholar
• Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res.46(11), 5629–5632 (1986).
   PubMed Web of Science ®Google Scholar
• Connolly DT, Olander JV, Heuvelman D et al. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem.264(33), 20017–20024 (1989).
   PubMed Web of Science ®Google Scholar
• Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res.50(6), 1774–1778 (1990).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun.161(2), 851–858 (1989).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246(4935), 1306–1309 (1989).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380(6573), 435–439 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380(6573), 439–442 (1996).
   PubMed Web of Science ®Google Scholar
• Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature376(6535), 62–66 (1995).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J. Clin. Oncol.23(6), 1295–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.65(3), 671–680 (2005).
   PubMed Web of Science ®Google Scholar
• Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother.38(7–8), 1258–1264 (2004).
   PubMed Web of Science ®Google Scholar
• AVASTIN® package insert. Genentech, CA, USA (2004).
   Google Scholar
• Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist10(6), 382–391 (2005).
   PubMed Web of Science ®Google Scholar
• Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis7(4), 335–345 (2004).
   PubMedGoogle Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med.77(7), 527–543 (1999).
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57(20), 4593–4599 (1997).
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res.60(8), 2178–2189 (2000).
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science312(5777), 1171–1175 (2006).
   PubMed Web of Science ®Google Scholar
• Augustin HG. Translating angiogenesis research into the clinic: the challenges ahead. Br. J. Radiol.76(Spec. No. 1), S3–S10 (2003).
   Google Scholar
• Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol.19(3), 843–850 (2001).
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat. Med.7(9), 987–989 (2001).
   PubMed Web of Science ®Google Scholar
• Brower V. Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors. J. Natl Cancer Inst.95(19), 1425–1427 (2003).
   Google Scholar
• Rubenstein JL, Kim J, Ozawa T et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia.2(4), 306–314 (2000).
   PubMed Web of Science ®Google Scholar
• Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med.1(2), 149–153 (1995).
   PubMed Web of Science ®Google Scholar
• Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by antivascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res.56(17), 4032–4039 (1996).
   PubMed Web of Science ®Google Scholar
• Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer88(12), 1979–1986 (2003).
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol.19(3), 851–856 (2001).
   PubMed Web of Science ®Google Scholar
• Adams J, Carder PJ, Downey S et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res.60(11), 2898–2905 (2000).
   PubMed Web of Science ®Google Scholar
• AVASTIN® product monograph. Hoffmann-La Roche Limited, ON, Canada (2005).
   Google Scholar
• Lin YS, Nguyen C, Mendoza JL et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther.288(1), 371–378 (1999).
   PubMed Web of Science ®Google Scholar
• BC Cancer Agency Gastrointestinal Tumour Group (UGICIRB). BCCA Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine. Cancer Agency, Vancouver, BC, Canada (2006).
   Google Scholar
• Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am. J. Hypertens.23(5), 460–468 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol.22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta. Oncol.49(3), 287–297 (2010).
   PubMed Web of Science ®Google Scholar
• Shord SS, Bressler LR, Tierney LA, Cuellar S, George A. Understanding and managing the possible adverse effects associated with bevacizumab. Am. J. Health Syst. Pharm.66(11), 999–1013 (2009).
   PubMed Web of Science ®Google Scholar
• AVASTIN® prescribing information. Genentech Inc., CA, USA (2011).
   Google Scholar
• George Sledge KM, Novotny W, Gaudreault J, Ash M, Cobleigh M. A Phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol.19 (2000) (Abstract 5C).
   Google Scholar
• Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J. Am. Soc. Nephrol.21(8), 1381–1389 (2010).
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21(1), 60–65 (2003).
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass HO Jr, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol.7(10), 1419–1426 (1989).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355(9209), 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Knight RLM, Pirotta N, Elfring G, Locker P, Saltz L. First-line irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) Patients (PT) with favorable prognostic indicators. Proc. Am. Soc. Clin. Oncol.19 (2000) (Abstract 991).
   Google Scholar
• Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur. J. Cancer32A(Suppl. 3), S18–S23 (1996).
   Google Scholar
• Rothenberg ML, Cox JV, DeVore RF et al. A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer85(4), 786–795 (1999).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol.23(16), 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol.23(16), 3706–3712 (2005).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med.352(5), 476–487 (2005).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRITE). J. Clin. Oncol.26(33), 5326–5334 (2008).
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Rodenburg CJ et al. A randomised Phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann. Oncol.19(4), 734–738 (2008).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T et al. A randomized Phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol.27(5), 672–680 (2009).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz HJ, Kindler HL et al. Randomized Phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol.25(29), 4557–4561 (2007).
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol.29(1), 11–16 (2011).
   PubMed Web of Science ®Google Scholar
• De Gramont A, Van Cutsem E, Tabernero J et al. AVANT: results from a randomized, three-arm multinational Phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J. Clin. Oncol.29(Suppl. 4), (2011) (Abstract 362).
   Google Scholar
• Lonser RR, Glenn GM, Walther M et al. von Hippel–Lindau disease. Lancet361(9374), 2059–2067 (2003).
   PubMed Web of Science ®Google Scholar
• Couch V, Lindor NM, Karnes PS, Michels VV. von Hippel–Lindau disease. Mayo Clin. Proc.75(3), 265–272 (2000).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol.23(31), 7889–7896 (2005).
   PubMed Web of Science ®Google Scholar
• Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol.23(5), 1028–1043 (2005).
   PubMed Web of Science ®Google Scholar
• Bukowski RM. Metastatic clear-cell carcinoma of the kidney: therapeutic role of bevacizumab. Cancer Manag. Res.2, 83–96 (2010).
   PubMedGoogle Scholar
• Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol.28(13), 2137–2143 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson Coon JS, Liu Z, Hoyle M et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br. J. Cancer101(2), 238–243 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia JA, Mekhail T, Elson P et al. Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a Phase II trial. BJU Int.107(4), 562–570 (2011).
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(9), 1432–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Sosman JA, Flaherty KT, Atkins MB et al. Updated results of Phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 5011).
   Google Scholar
• Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol.26(Suppl.), (2008) (Abstract 5010).
   Google Scholar
• Escudier B. How to interpret Phase II data for everolimus plus bevacizumab in renal cell carcinoma. J. Clin. Oncol.28(13), 2125–2126 (2010).
   Google Scholar
• Jonasch E, Wood CG, Matin SF et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(25), 4076–4081 (2009).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23(4), 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol.28(20), 3239–3247 (2010).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Miller KD, Sissons SE et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res.61(8), 3369–3372 (2001).
   PubMed Web of Science ®Google Scholar
• Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol.29(10), 1252–1260 (2011).
   PubMed Web of Science ®Google Scholar
• D’Agostino RB SR. Changing end points in breast-cancer drug approval – the Avastin story. N. Engl. J. Med.365(2), e2 (2011).
   PubMedGoogle Scholar
• Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother. Pharmacol.41(6), 497–504 (1998).
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J. Clin. Oncol.27(8), 1227–1234 (2009).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised Phase III trial (AVAIL). Ann. Oncol.21(9), 1804–1809 (2010).
   PubMed Web of Science ®Google Scholar
• Crino L, Dansin E, Garrido P et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a Phase 4 study. Lancet11(8), 733–740 (2010).
   Google Scholar
• Adjei AA, Mandrekar SJ, Dy GK et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J. Clin. Oncol.28(4), 614–619 (2010).
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small-cell lung cancer. J. Thorac. Oncol.3(5), 511–515 (2008).
   PubMed Web of Science ®Google Scholar
• Heist RS, Fidias P, Huberman M et al. A Phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J. Thorac. Oncol.3(10), 1153–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas M, Reuss A, Fischer JR et al. Randomized Phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small-cell lung cancer (NSCLC). J. Clin. Oncol.29(Suppl.), (2011) (Abstract 7504).
   Google Scholar
• Malhotra B, Evans T, Weiss J et al. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience. Clin. Lung Cancer11(3), 192–197 (2010).
   PubMed Web of Science ®Google Scholar
• Patel JD, Hensing TA, Rademaker A et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol.27(20), 3284–3289 (2009).
   PubMed Web of Science ®Google Scholar
• Reynolds C, Barrera D, Jotte R et al. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small-cell lung cancer. J. Thorac. Oncol.4(12), 1537–1543 (2009).
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Dahlberg SE, Keller SM, Gandara DR et al. Interim report of on-study demographics and toxicity from E1505, a Phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small-cell lung cancer (NSCLC). J. Clin. Oncol.29(Suppl.), (2011) (Abstract 7013).
   Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17(8), 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27(28), 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27(5), 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS; the BRAIN Investigators. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol.28(Suppl.), 15s (2010) (Abstract 2008).
   Google Scholar
• Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol.29(2), 142–148 (2011).
   PubMed Web of Science ®Google Scholar
• Quant E, Norden AD, Drappatz J, Ciampa A. Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J. Clin. Oncol.26(Suppl.), (2008) (Abstract 2008).
   Google Scholar
• Zuniga RM, Torcuator R, Jain R et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J. Neurooncol.99(2), 237–242 (2010).
   PubMed Web of Science ®Google Scholar
• Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J. Clin. Oncol.28(Suppl.), 18s (2010) (Abstract LBA1).
   Google Scholar
• Perren T, Swart AM, Pfisterer J et al.; GCIG ICON7 Collaborators. ICON7: a Phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC). Presented at: The 35th ESMO Congress. Milan, Italy, 8–12 October 2010.
   Google Scholar